Category Archives: Stell Cell Research


Global Cord Blood Stem Cell Market Newest Research Report In PDF With Forecast [2020-2029] : Cord Blood Registry Systems Inc, Viacord Inc., China Cord…

The new research report providing thorough analysis on GlobalCord Blood Stem Cell Marketwhich peaks the market size, inclusive market dynamics and high technology updates of Cord Blood Stem Cell market with respect to industry opportunities, threats, challenges, constraints, cost structure and current trend in the market. The Cord Blood Stem Cell industry report is a thorough study of the market where the customer can gain key intuition into the market such as the performance of the market in terms of its market (size and value) for its various segmentations such as storage service, application, and region. This research assists to understand the competitive outlook of Cord Blood Stem Cell market by key players Cord Blood Registry Systems Inc, Viacord Inc., China Cord Blood Corporation., Cord Blood America Inc, Cryo-Cell International Inc, Cryo-Save AG., Cordlife Group Ltd., Vita 34 AG., Lifecell International Pvt. Ltd., Stemcyte Inc..

The research report consists of primary and secondary data which has been further epitomized through various charts, bar graphs, pie charts, tables and market figures. Additionally, detailed landscaping, Cord Blood Stem Cell economic strategy, marketing scheme, as well as SWOT analysis & Porte Five Forces Analysis of the market players have been provided in the Cord Blood Stem Cell report. It also includes the inventive trends, executing a rational pricing stats in the competitive Cord Blood Stem Cell market. The report also categorizes the market in terms of volume and revenue [Million USD].

To Obtain All-Inclusive Information On Forecast Analysis Of GlobalCord Blood Stem CellMarket, Download FREE SamplePDF Report Herehttps://marketresearch.biz/report/cord-blood-stem-cells-market/request-sample

The Cord Blood Stem Cell market report covers revenue number, product details, and sales of the leading Cord Blood Stem Cell corporations. The international market for Cord Blood Stem Cell has been researched with every detail in the publication with increased prominence on various important factors such as opportunities, and self-controlled, growth drivers. Each of the factors that concern to creation of the Cord Blood Stem Cell market dynamics has been studied and analyzed in detail by the Cord Blood Stem Cell analysts, so as to offer the best and most assessing and comprehensive study to the buyers of Cord Blood Stem Cell report.

The snapshot or the directional summary that has been provided in the Cord Blood Stem Cell market intelligence study has been designed in such a way that it will give a quick overview of the market for receiving information on the go. This could assist Cord Blood Stem Cell readers with hands-on data required for decision making during their progress journey in the Cord Blood Stem Cell market.

Global Cord Blood Stem Cell Market Research Report 2020-2029 Includes

Download Free Sample PDF Copy of This Research Report Now!

Geographically, this Cord Blood Stem Cell report is divided into different key regions, with production, Cord Blood Stem Cell utilization, income (million USD), and market share and the rate of growth in these regions, from 2020 to 2029 (forecast), covering Cord Blood Stem Cell market in North America (U.S., Canada, Mexico), Europe (Germany, U.K., France, Italy, Russia, Spain, etc), South America (Brazil, Argentina, etc), Middle East & Africa Cord Blood Stem Cell market (Saudi Arabia, South Africa, etc) and its Share (%) and CAGR for the predicted period 2020 to 2029.

The Key Points of this Cord Blood Stem Cell Market Report are:

1) To survey and forecast the market size share of Cord Blood Stem Cell, in terms of value and volume.

2) Provide detailed information concerning the Cord Blood Stem Cell major factors (opportunities, drivers, restraints, and industry-specific challenges) influencing the growth of Cord Blood Stem Cell market.

3) To study the future outlook and prospects for the Cord Blood Stem Cell market with Marketing Price (Price and Margin, Factors of Price Change, Manufacturers Gross Margin Analysis)

4) To analyze the global key regions Cord Blood Stem Cell market potential and advantage, opportunity and challenge, restraints and risks.

5) Detail Profile of the dominant players and Cord Blood Stem Cell comprehensively analyses their market status in terms of ranking and core capability along with in-depth the Cord Blood Stem Cell competitive landscape for the market leaders.

6) Study competitive developments like partnerships and joint ventures, Cord Blood Stem Cell new product developments, expansions and research and development of Cord Blood Stem Cell market.

Inquire/Speak To Expert for Further Detailed Information About Cord Blood Stem Cell Report:https://marketresearch.biz/report/cord-blood-stem-cells-market/#inquiry

Note: The historical years of the report and the forecast period can be personalized upon request. [Post Your Research Requirements] In addition, the scope of the published report can be changed as needed, detailed geography or country-based information can be given as part of the customization process.

About Us:

MarketResearch.Biz is a specialized market research, analytics, and solutions company, offering strategic and tactical support to clients for making well-informed business decisions. We are a team of dedicated and impassioned individuals, who believe strongly in giving our very best to what we do and we never back down from any challenge. The company offers services such as data mining, information management, and revenue enhancement solutions and suggestions. We cater to industries, individuals, and organizations across the globe, and deliver our offerings in the shortest possible turnaround time.

Contact Us:

Mr. Benni Johnson (inquiry@marketresearch.biz)

MarketResearch.Biz (Powered By Prudour Pvt. Ltd.)

420 Lexington Avenue, Suite 300

New York City, NY 10170,

United States

Website:https://marketresearch.biz

See the rest here:
Global Cord Blood Stem Cell Market Newest Research Report In PDF With Forecast [2020-2029] : Cord Blood Registry Systems Inc, Viacord Inc., China Cord...

State of the Science for Multiple Myeloma: Change in the Right Direction – Cancer Network

In a workshop held by the FDA in partnership with the American Association for Cancer Research (AACR) on February 13, 2019 in Wardman Park, Washington D.C., researchers from various institutions discussed the current state of African American outcomes and treatment in multiple myeloma trials and the clinical implications.

Although theres still this disparity, the rate of change in the right direction seems to be similar [for Caucasian and African American populations], Kenneth C. Anderson, MD, FAACR, program director for the Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics at the Dana-Farber Cancer Institute, said of the findings.

In an analysis based on preliminary FDA findings that suggested there was limited enrollment of African Americans in multiple myeloma clinical trials, researchers looked to see if there were differences in outcomes due to race and if there are differences in screen failure rates that contribute to differences in enrollment. Additionally, they looked to address if eligibility criteria are restrictive for certain demographic subgroups.

The presenters, Laura Fernandes, PhD, and Bindu Kanapuru, MD, of the FDA, summarized that enrollment of black patients was significantly less in their pooled dataset compared to white patients. Additionally, there were no conclusive differences in the different racial categories in regard to overall response rate, progression-free survival, and overall survival.

Moreover, more black patients failed to meet the screening criteria than their white and Asian study counterparts. In regard to the screen failure analysis, Kanapuru said, In general, fewer black patients were screened compared to whites and Asians. Second, among those who were screened for enrollment onto the multiple myeloma clinical trials, there is a trend towards higher screen failure rates for blacks compared to white.

Notably, Kanapuru indicated that the FDA has several ongoing initiatives and also published several guidances in an effort to expand eligibility criteria.

Moreover, in an evaluation of characteristics and outcomes of patients with multiple myeloma from an EHR-derived database, Kathleen Maignan, MSN, NP, from Flatiron Health, suggested that researchers were able to assess outcomes in patient subgroups that are likely to have lower representation or even be excluded from trials. Unadjusted results from the database indicated that black patients have similar or better outcomes when compared to white patients. However, adjusting for age and sex minimized this difference, especially for overall survival.

While real world data does have more African American patients, the representation still is not the same, Maignan said.

The research also suggested that black patients have a higher comorbidity burden, which could minimize their consideration for future trials. So, when we look at future directions, given the higher comorbidity burden amongst black patients, we see a potential to conduct future work in this subgroup which may have an unmet need, Maignan said. We also look forward to opportunities to further investigate genomic differences by race as we expand our clinical genomics database and availability there.

Furthermore, covering the scope of the issues, Nikhil C. Munshi, MD, of the Dana-Farber Cancer Institute, indicated that race has significant influence on outcomes and overall survival, as well as age within the different racial groups. Physiological and microenvironment parameters may also play a role with racial differences on outcomes in myeloma according to the researcher. Additionally, traditional prognostic factors may still have variability across racial differences.

So, the critical question now is to study the biological basis for these differences using genomics and all of the different technologies that are directly available to us, Munshi said. Moreover, he recommended that researchers studying patients with multiple myeloma evaluate the impact of race on therapeutic intervention and their PK/PD, as well as disease sensitivity compared to disease resistance.

Looking at biological and genomic differences of multiple myeloma, Shaji K. Kumar, MD, from the Mayo Clinic Cancer Center, Kumar indicated that MGUS is 2-3 times more common in African Americans, which correlates with the fact that myeloma is 2-3 times more common as well. Additionally, he found that there was a trend to earlier age of onset MGUS in blacks compare to whites, with the disparity in prevalence between blacks and whites being most striking within the 40-49 age group (3.26% [95% CI, 2.04-5.18] vs 0.53% [95% CI, 0.20-1.37];P= 0.0013).

I think we want to think about this differently, said Kumar. We are talking about a group of patients who get diagnosed about 10 years younger, who have better biology because of the fundamental underlying genetic differences, despite having advancements at diagnosis they tend to do better, so really the actual setting should be the African Americans should be doing a lot better than what theyre doing now.

The researcher then indicated that important role for screening in the African American patient population, especially with research showing that earlier screening would be beneficial in multiple myeloma. By treating them earlier, he presents the idea that their outcomes could actually be even better than the Caucasian patients. Additionally, Kumar indicated that the access to therapy, specifically stem cell therapy, needs to be addressed.

In the final presentation, Ajay K. Nooka, MD, from the Winship Cancer Institute of Emory University, discussed how to increase minority accrual in myeloma clinical trials through experiences and lessons learned within his own institution. At the system level, a lack of clinical trial infrastructure and insurance were the most prevalent barriers. At the individual level, a lack of trust, fear related to research participation, inadequate information about research, and access/convenience of participation all presented as barriers for clinical trial enrollment.

He listed some solutions that physicians within his institution brought attention to, including:

Following the presentation of the state of the science at the workshop, working groups presented recommendations for how to combat the addressed disparities in African American representation within multiple myeloma clinical trials.

Reference:

FDA-AACR Workshop to Examine Under-representation of African Americans in Multiple Myeloma Clinical Trials. Held Feb. 13, 2020. Wardman Park, Washington D.C.

View original post here:
State of the Science for Multiple Myeloma: Change in the Right Direction - Cancer Network

San Diego News Icon Don Bauder Gives His Heart to Ideal Candidate Bloomberg – Times of San Diego

Share This Article:Mike Bloomberg has a new fan in retired San Diego business journalist and columnist Don Bauder (inset). Photos by Chris Stone, Ellen BauderAt 83, San Diego journalism legend Don Bauder is guarding his health playing hermit at home (to avoid the flu) and venturing out only for doctor visits.

Support Times of San Diego's growthwith a small monthly contribution

Bauder, a Colorado resident since 2003, was forced by heart issues to retire in 2018 as a San Diego Reader columnist. But now he admits hell be questioned about his mental health.

Hes backing Mike Bloomberg for president.

Here I am finally making headway against the heart problems and now I am considered a candidate for the loony bin, Bauder said by email Wednesday.

If exercise and multiple trips to doctors and hospitals will repair my brain as they seem to have helped my heart, I feel I can thwart oncoming dementia, although I have never claimed that I am either stable or a genius as President Donald Trump has. I am at least stable enough to hope that my candidate will not choke on verbal borscht, as Trump does almost every day.

Bauder isnt wearing rose-colored glasses, though.

He concedes that the former New York City mayor once stated that if women wanted to be known for their intelligence, they would spend less time at Bloomingdales and more time at the library.

Bloomberg called the remark a Borscht Belt joke, Bauder said.

The former San Diego Union-Tribune financial editor also noted that Bloomberg once stated that 95% of murderers are male minorities, 15 to 25 who deserve to be pushed up against the wall.

Bauder adds: Democrats desperately need the votes of women, African-Americans and Latinos. New Yorkers have told me that those minorities will never forget, although Bloomberg has renounced his widely criticized stop-and-frisk policy that clearly discriminated against minorities while he was mayor of New York.

But it wasnt until former U-T colleague Logan Jenkins outed himself as a Bloomberg fan that Bauder also emerged from the closet at least locally.

Bauder wrote Times of San Diego:

As a former newspaper columnist and magazine writer, I agree wholeheartedly with Logan Jenkins. After a lot of pondering, I have concluded that Bloomberg is the ideal Democratic candidate. I started out backing Biden, but have become quite disenchanted. Unlike Trump, Bloomberg is a self-made billionaire.

Unlike Trump, who is clearly a sociopath on steroids, as well as a pathological liar and malignant psychotic narcissist, Bloomberg is eminently stable and also brilliant, as he proved in his business career and as mayor of New York City. I would add one thing to what Logan says: we desperately need a female on the ticket. As shown in 2018, females can see through Trump.

I would suggest Kamala Harris; her minority status would help balance the ticket. I worry that Bloombergs stop and frisk mistake will continue to turn off minorities.

Like Bloomberg, Bauder is a former Republican. (From 1960 to 1964, when he was in advertising and PR, Bauder voted for Richard Nixon.)

Since 2004, he says, hes voted for Democratic presidential candidates.

This year, however, I had problems, he wrote Wednesday. I feared that both Bernie Sanders and Elizabeth Warren had gone too far. I dont like Medicare for All. Those who want to keep their private plans should be able to do so. I cant see free higher education for all. Frankly, I think too many students are in college now.

Bauder calls student debt a cancerous problem, but cant see canceling it out.

Should we reimburse those who have already paid off their debt? I cant see giving stipends to families descended from slaves, he said. If anybody deserves to be paid off, its Native Americans, from whom we stole our country.

He said his cautious views left him with moderate choices.

I originally favored Joe Biden, but became disenchanted quickly. I liked Amy Klobuchar from the beginning, and I am happy to see her rising fast, he said. Pete Buttigieg is quite intelligent but needs seasoning. Ditto Tom Steyer.

Bauder considers the 2020 election critical.

Four more years of Trump would be disastrous, he said. Yes, I am concerned about more Russian hacking. Given the close 2016 races in Wisconsin, Michigan and Pennsylvania, we should all worry about Russian hacking this year.

Climate change is the most critical issue for Bauder because if the world doesnt do more to curb greenhouse gases, the world as we know it may suffocate by the end of the century.

This interview was conducted via email.

Times of San Diego: What does Mike Bloomberg offer?

Don Bauder: First: money. Lots of it. Hes worth close to $60 billion, making him 14th-richest in the world, according to Forbes. Unlike Trump, Bloomberg made the money himself. And he is ACTUALLY worth that.

Trump may not even be a billionaire, despite his claims to be worth $10 billion. The biggest advantage of Bloombergs wealth is that he can flood the nation with ads showing that Trump is a phony. Indeed, Bloomberg is already doing that, but you aint seen nuthin yet.

The Democratic Party is hurting for money. Bloomberg is NEEDED. He has not alienated the business community. Right now, money is flowing to Republican coffers because big business particularly pharmaceuticals, insurance, oil and the like is terrified of Sanders and Warren. That river of cash will slow down if the leftists are out of the picture.

As he has proved as New York mayor, Bloomberg is socially liberal and progressive. He supports abortion rights, government-funded stem cell research, same-sex marriage, gun control, environmentalism and routes to citizenship for illegal immigrants.

He is strong on public welfare and is a national leader in the battle against climate change. He wants to enhance the earned income tax credit. But unlike the other candidates, he has support from many in the business community. He is in favor of free trade. He is a fiscal conservative. He balanced New York Citys budget. Facing a crisis, he talked a Republican state Senate into passing a tax increase rather than slashing jobs.

He opposes wealth inequality proposing, for example, that his own taxes should go up. He says generally that taxes for the rich should rise. He would raise corporate taxes from 21% to 28% percent not enough in my judgment, but a good start.

He dislikes the fact that taxes on stock and bond gains are lower than income taxes. He would enhance worker rights and benefits although he has never been considered pro-union. He wants a $15 an hour minimum wage. He favors government-financed welfare projects. He believes rural communities should be more closely connected with urban centers.

During his political career, he has been a Republican, an independent and a Democrat. He knows his way around politics, having been mayor of New York City from 2002 to 2013.

He cracked one time that a short Jew would never be elected president, but I question that. He will absolutely eat up Trump in a debate. It will be obvious that he is 10 times smarter than Trump.

(Bauder cites the same metric in the San Diego mayors race, saying he favors Barbara Bry because of her intelligence.)

Your journalism career is marked by major investigations into scam artists and political boondoggles. What gives you confidence that Bloomberg has genuine concern for the common good and not himself and his affluent cohort?

He favors corporate welfare corporate projects partly funded by government. I consider most such projects to be scams, although few others do. As mayor of New York, he has warned the citizenry of scam artists on the loose. But early in his mayoral term he vetoed a bill against predatory lending.

Why should Sen. Kamala Harris be Bloombergs running mate?

First, the Democrats must have a female on the ticket on the top of the ticket or the vice president. If Bloomberg is at the top, a female must run for the second slot. A minority female would be greatly preferred. Kamala Harris fills that bill. Stacey Abrams or Oprah Winfrey (who says she doesnt want it) would also be excellent.

If Bloomberg doesnt break out in Super Tuesday voting, will he have a shot at winning enough delegates to prevail at Milwaukee Democratic National Convention?

If Bloomberg does poorly, he will have to consider dropping out. If he does drop out, he should continue giving his planned donations to the Democratic Party. Ditto Tom Steyer. Both must continue to give if they are no longer candidates. The Democratic Party is not in good financial shape. If Bloomberg loses, I would hope Sherrod Brown, senator of Ohio, would get in the race.

Bloomberg has credibility from his mayor terms and gun-control and climate-change work. But he was elected in a very liberal environment. Could he challenge Trump in red states?

You make a good point that Bloomberg might not go over well in red states where uneducated voters are abundant. Many Americans hate New Yorkers unfortunately, often for good reasons. But although Bloomberg is short in stature, many voters will realize that he would be the real alpha male in the race. He is tough and knowledgeable. He would take hard stands on many issues.

Handicap a Trump vs. Sanders contest.

Trump has already called Sanders a communist not a socialist, which he is. So we would have a rerun of Joe McCarthy. If Trump continues to call Sanders a communist, Democrats should call Trump and his ilk fascists. Down and dirty. I think Sanders would take the West Coast and most of the East Coast, including Florida.

But Trump would take states where education levels are low the South, and Northern states such as Montana, Wyoming, Idaho, North and South Dakota, Kansas, Nebraska and other traditionally red (redneck?) states. Colorado, New Mexico and even possibly Arizona could go for Sanders.

Ohio, Indiana and Iowa could go red and Wisconsin and Minnesota might go blue. Illinois could stay blue. Much depends on whether Americans realize that Trump is a pathological liar, sociopath, malignant psychotic narcissist. He seems totally out of control now.

Critics like Paul Heideman call Bloomberg a classic oligarch using his wealth to tilt the economic and political playing field in his favor. Can voters trust someone who uses vast wealth to gain support? How is billionaire Bloomberg better suited to the Oval Office than billionaire Steyer (or anyone else)?

Paul Heideman has a point. You are correct that some voters will see how many ads he spreads around and hold his wealth against him. But these people could be swayed by the wave of advertising.

What Bloomberg can do is massively sponsor ads that emphasize that Trump is a liar showing him saying one thing one day and the opposite the next day. Also, such ads could show that Trumps claims about the economy on his watch are false.

For example, Trump keeps repeating that the economy has done better under him than at other times. This is laughably false. GDP is growing a little over 2% now and there have been many times when it grew 3% and even 4%. Trump says unemployment is the lowest ever, and that is also false. These ads can also show Trump at his most vulgar. That might even go over well in redneck territory, however. Trumps racism through his dog whistles could be emphasized in certain markets but not in redneck areas.

Would Bloomberg address wealth inequality?

Bloomberg is strongly opposed to wealth inequality and says his own taxes should go up. However, he would only raise the corporate tax rate to 28% from 21%. Thats not enough, in my judgment. He believes income taxes for the rich should be boosted. He is also disgusted that taxes on stock and bond profits are lower than taxes on incomes.

He complains that economic growth is concentrated in a small number of regions. He would enhance worker rights and benefits although he has never been known as pro-union a possible negative. He wants a $15 minimum wage. He favors government-financed welfare projects. He would like to see rural communities better connected to urban growth centers. He wants to see research and development in regions needing development.

How is your health?

I saw my cardiologist just two weeks ago. I asked him if I was a candidate for a stent in my two arteries that are only moderately good. He said no. (Background: I have had two quadruple-bypass surgeries. The last one was in 1990. On average, the grafts last 30 years.) But cardiologists (I have had several) say this does not mean I have only two years to go.

The heart itself seems to be OK, but the concern is arteries or grafts from previous surgeries filling up. I will be 84 in May. I dont expect to make it to 90, but with lots of luck I may get half or a third of the way there.

San Diego News Icon Don Bauder Gives His Heart to Ideal Candidate Bloomberg was last modified: February 14th, 2020 by Ken Stone

>> Subscribe to Times of San Diegos free daily email newsletter! Click here

Read this article:
San Diego News Icon Don Bauder Gives His Heart to Ideal Candidate Bloomberg - Times of San Diego

The F.D.A. Will Now Allow Lab Animals to Be Adopted – Smithsonian.com

The Food and Drug Administration will now put healthy research animals up for adoption after their time in the lab is complete. The new rule affects dogs, cats, rabbits, guinea pigs and some farm animal species, reports The Hills Rachel Bucchino.

The F.D.A. uses animal testing to understand the effects of medical products, like drugs, vaccines and medical devices, before research can move to clinical trials involving humans. Per the F.D.A., animal research is necessary to understand attributes like how quickly a medication is absorbed by the body and how quickly its effects wear off. Animal testing also gives insight into any toxic byproducts that show up as the drug is broken down and how long those byproducts remain in the body. Medical devices that are made from new materials need to be tested in animals for the same reasons.

In the past, research animals were generally euthanized at the end of research, even if they were healthy. But in November, the F.D.A. updated their policies to encourage lab animal retirementadoption into furever homes. The change wasnt publicly disclosed by the F.D.A. until now.

The FDA has an internal policy for the placement of research animals after study completion that has not been made public, Monique Richards, an F.D.A. spokeswoman, told The Hill.

The new policy follows suit with the National Institutes of Health, which enacted a similar policy in August of last year, and the Department of Veteran Affairs, which put a policy in place encouraging adoption of research dogs in 2018. Several states have laws encouraging labs to find adopters for common domestic animals used in their research, but no nationwide requirement currently exists.

In 2019, an animal advocacy group called the White Coat Waste Project brought scrutiny against a USDA research program studying toxoplasmosis. Toxoplasmosis eggs are spread through cat feces, so the researchers fed kittens tainted dog and cat meat to infect them with the parasite, which relies on cats as part of its life cycle. Between 2013 and 2018, 239 cats were killed in the study, per NPRs Vanessa Romo, and after WCWs report the USDA shut down all cat experiments and adopted out 14 healthy cats.

In 2019, U.S. Senator Susan Collins of Maine introduced the Animal Freedom from Testing, Experiments and Research (AFTER) Act, which would put a nationwide policy in place regarding animal adoptions after a life in the lab.

There is no reason why regulated research animals that are suitable for adoption or retirement should be killed by our federal agencies, Collins said in a statement to The Hill. Im pleased that the FDA has joined the NIH and VA in enacting a lab animal retirement policy.

Julie Germany, executive director of the White Coat Waste Project, adopted a dog named Violet from a government-funded lab. At first, Violet was extremely anxious, having grown up in a lab and never seen the outdoors, Germany tells The Dodos Arin Greenwood. Violet hadnt been house trained and needed a diaper, and was taught by the family cat, Bert, how to climb the stairs. But by 2017, Violet became well-adjusted to life in a loving home.

The FDA should be a role model for other federal agencies that are experimenting on animals, but have not yet agreed to allow them to be released at the end of testing, Justin Goodman, vice president of the White Coat Waste Project, tells The Hill.

The United States 2020 budgetary spending bill also contains goals to reduce the use of dogs and cats in federally funded medical research. Some researchers have expressed concern over the new legislation, which represents the first time Congress has set "hard deadlines for the elimination and reduction of experiments on dogs, cats and primates," Goodman told Science magazines David Grimm in 2019.

There is some language that could set a dangerous precedent for deciding how research in the U.S. should be conducted in the future, explains Matthew Bailey, president of the National Association for Biomedical Research, in a 2019 interview with Science. Today, it is animals in biomedical research; tomorrow, it may be climate science, tobacco research, stem cell research, occupational health research, or even epidemiology.

He adds, Eventually that research will be more likely to move to other countries, which isnt good for American competitiveness, animal welfare, or the publics health.

Go here to read the rest:
The F.D.A. Will Now Allow Lab Animals to Be Adopted - Smithsonian.com

Stem Cell Assay Market 2020 Booming by Size, Revenue, Trend and Top Companies 2026 – Instant Tech News

New Jersey, United States, The report titled, Stem Cell Assay Market Size and Forecast 2026 in Verified Market Research offers its latest report on the global Stem Cell Assay market that includes comprehensive analysis on a range of subjects like competition, segmentation, regional expansion, and market dynamics. The report sheds light on future trends, key opportunities, top regions, leading segments, the competitive landscape, and several other aspects of the Stem Cell Assay market. Get access to crucial market information. Market players can use the report back to peep into the longer term of the worldwide Stem Cell Assay market and convey important changes to their operating style and marketing tactics to realize sustained growth.

Global Stem Cell Assay market was valued at USD 536.53million in 2016 and is projected to reach USD 2858.95millionby 2025, growing at a CAGR of 20.43% from 2017 to 2025.

Get | Download Sample Copy @https://www.verifiedmarketresearch.com/download-sample/?rid=24266&utm_source=ITN&utm_medium=002

Top 10 Companies in the Global Stem Cell Assay Market Research Report:

Global Stem Cell Assay Market: Competitive Landscape

Competitive landscape of a market explains strategies incorporated by key players of the market. Key developments and shift in management in the recent years by players has been explained through company profiling. This helps readers to understand the trends that will accelerate the growth of market. It also includes investment strategies, marketing strategies, and product development plans adopted by major players of the market. The market forecast will help readers make better investments.

Global Stem Cell Assay Market: Drivers and Restrains

This section of the report discusses various drivers and restrains that have shaped the global market. The detailed study of numerous drivers of the market enable readers to get a clear perspective of the market, which includes market environment, government policies, product innovations, breakthroughs, and market risks.

The research report also points out the myriad opportunities, challenges, and market barriers present in the Global Stem Cell Assay Market. The comprehensive nature of the information will help the reader determine and plan strategies to benefit from. Restrains, challenges, and market barriers also help the reader to understand how the company can prevent itself from facing downfall.

Global Stem Cell Assay Market: Segment Analysis

This section of the report includes segmentation such as application, product type, and end user. These segmentations aid in determining parts of market that will progress more than others. The segmentation analysis provides information about the key elements that are thriving the specific segments better than others. It helps readers to understand strategies to make sound investments. The Global Stem Cell Assay Market is segmented on the basis of product type, applications, and its end users.

Global Stem Cell Assay Market: Regional Analysis

This part of the report includes detailed information of the market in different regions. Each region offers different scope to the market as each region has different government policy and other factors. The regions included in the report are North America, South America, Europe, Asia Pacific, and the Middle East. Information about different region helps the reader to understand global market better.

Ask for Discount @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=24266&utm_source=ITN&utm_medium=002

Table of Content

1 Introduction of Stem Cell Assay Market

1.1 Overview of the Market 1.2 Scope of Report 1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining 3.2 Validation 3.3 Primary Interviews 3.4 List of Data Sources

4 Stem Cell Assay Market Outlook

4.1 Overview 4.2 Market Dynamics 4.2.1 Drivers 4.2.2 Restraints 4.2.3 Opportunities 4.3 Porters Five Force Model 4.4 Value Chain Analysis

5 Stem Cell Assay Market, By Deployment Model

5.1 Overview

6 Stem Cell Assay Market, By Solution

6.1 Overview

7 Stem Cell Assay Market, By Vertical

7.1 Overview

8 Stem Cell Assay Market, By Geography

8.1 Overview 8.2 North America 8.2.1 U.S. 8.2.2 Canada 8.2.3 Mexico 8.3 Europe 8.3.1 Germany 8.3.2 U.K. 8.3.3 France 8.3.4 Rest of Europe 8.4 Asia Pacific 8.4.1 China 8.4.2 Japan 8.4.3 India 8.4.4 Rest of Asia Pacific 8.5 Rest of the World 8.5.1 Latin America 8.5.2 Middle East

9 Stem Cell Assay Market Competitive Landscape

9.1 Overview 9.2 Company Market Ranking 9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview 10.1.2 Financial Performance 10.1.3 Product Outlook 10.1.4 Key Developments

11 Appendix

11.1 Related Research

Request Customization of Report Complete Report is Available @ https://www.verifiedmarketresearch.com/product/Stem-Cell-Assay-Market/?utm_source=ITN&utm_medium=002

Highlights of Report

About Us:

Verified market research partners with clients to provide insight into strategic and growth analytics; data that help achieve business goals and targets. Our core values include trust, integrity, and authenticity for our clients.

Analysts with high expertise in data gathering and governance utilize industry techniques to collate and examine data at all stages. Our analysts are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research reports.

Contact Us:

Mr. Edwyne Fernandes Call: +1 (650) 781 4080 Email: [emailprotected]

TAGS: Stem Cell Assay Market Size, Stem Cell Assay Market Growth, Stem Cell Assay Market Forecast, Stem Cell Assay Market Analysis, Stem Cell Assay Market Trends, Stem Cell Assay Market

Read the original post:
Stem Cell Assay Market 2020 Booming by Size, Revenue, Trend and Top Companies 2026 - Instant Tech News

Attacking pancreatic cancer with the help of the virus that causes foot-and-mouth disease in cows – FierceBiotech

Pancreatic cancer remains difficult to treat, with five-year survival rate of less than10%. While looking for ways to tackle the deadly tumor, scientists at Queen Mary University of London, AstraZeneca and ADC Therapeutics identified an unexpected ally: the virus that causes foot-and-mouth disease in cows.

The researchers found that a peptide taken from the foot-and-mouth virus can seek out pancreatic cancer cells. Arming the peptide guide with a toxic warhead killed pancreatic tumors in mice and significantly prolonged the animals lifespans, according to a new study published in the journal Theranostics.

The peptide was taken from the VP1 coat protein of the foot-and-mouthvirus. It can target integrin v6, a protein thats overexpressed in most pancreatic cancers but is low or absent in the normal pancreas.

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Our previous research had shown that 84% of pancreatic cancer patients have high levels of v6 on their cancers, John Marshall, the studys senior author, explained in a statement. Foot-and-mouth-disease virus uses v6 as a route to infect cattle, as the virus binds to this protein on a cow's tongue. By testing pieces of the protein in the virus that attaches to v6, we've developed a route to deliver a drug specifically to pancreatic cancers.

Researchers linked the v6-specific peptide to the payload tesirine, a drug developed by Spirogen, which was boughtby AstraZeneca in 2013 in a $440 million deal.

Marshall and colleagues tested their peptide-drug conjugate, now dubbed SG3299, in cancer cells grown in lab dishes and in mouse models of pancreatic cancer. The drug killed off cancer cell lines, while a non-v6-targeting tesirine combo failed to bind to them, the team reported.

Cancer cells can form little spheres in lab dishes that are believed to help enrich the stem cell-like properties in pancreatic cells, which have been linked to tumor metastasis and development of treatment resistance. In patient-derived xenografts, the researchers found that SG3299 significantly reduced the number of spheres.

In mice, the drug also showed promising results. When used at a small dosage given three times a week, SG3299 significantly reduced the size of tumors. At an increased strength given bi-weekly, the drug eliminated tumors in four out of fivemiceand left just one small tumor in the other animal. The tumor reduction also translated into survival benefits. Mice that got SG3299 were all alive after 130 days, whereas those given avb6-specific peptide alone or a non-v6-targeting drug only posted median survival 62.5 days and 95 daysrespectively.

RELATED:Swiss biotech ADC Therapeutics guns for $150M IPO

The idea of delivering highly potent drug right to the cancer target resembles that of antibody-drug conjugates (ADCs), a technology thats already been applied in FDA-approved anticancer therapies such as Roches Kadcyla and Daiichi Sankyo and AstraZenecas Enhertu. Tesirine has also been used to design ADCs, perhaps most notably in AbbVies failed small-cell lung cancer med Rova-T (ravalpituzumab tesirine).

Swiss biotech ADC Therapeutics is backed by AstraZeneca and recently withdrew a potential $200 million initial public offering. The companys lead candidates, ADCT-402 and ADCT-301, also use tesirine in their constructs and theyre under clinical testing in blood cancers.

Marshalls team hopes targeting v6 with their peptide-drug conjugate could become a new weapon against pancreatic cancer.

One advantage of targeting v6 is that it is very specific to the cancerbecause most normal human tissues have little or none of this protein, he said. So we're hopeful that, if we can develop this into an effective treatment for pancreatic cancer, it would have limited side effects.

Moving forward, the team plans to further test SG3299 in more complex mice models to explore the drugs ability to stop cancer metastases before starting clinical trials.

See the rest here:
Attacking pancreatic cancer with the help of the virus that causes foot-and-mouth disease in cows - FierceBiotech

Stem Cell Artificial Meat : Industry Analysis and Forecast 2020 2025 By Key Players-, Beyond Meat, Impossible Foods, Memphis Meats, Boca Foods -…

Report Hive Research adds a new research study titled Stem Cell Artificial Meat Market report to its market intelligence database. This research report is a product of profound market analysis by our team of Research analysts, who are endowed with excellent research skills and years of experience. Our reports are majorly focused on, future trends, market outlook, market drivers, product consumption, production demand, revenue generation, sales volume, and many other important aspects linked to the market dynamics.

Along with focus laid on the important factors that have been positively influencing the Stem Cell Artificial Meat market growth over the forecast timeframe, the analysts have also put forth the restraining factors that are anticipated to slow down business growth in the upcoming future. This is because we believe in complete transparency rather than just shedding praises over the market, so as to sell the report. The challenges anticipated to hamper the market growth are pointed out along with proper guidelines to avoid the unpleasant market situations in the near future.

Key companies operational in the global Stem Cell Artificial Meat market mentioned in the report:

Beyond MeatImpossible FoodsMemphis MeatsBoca FoodsKelloggsMorningstar FarmsSulian

Stem Cell Artificial Meat market By Product Type:

Bovine Stem Cell Artificial MeatFish Stem Cell Artificial MeatOthers

Stem Cell Artificial Meat market By Application Type:

Bovine Stem Cell Artificial MeatFish Stem Cell Artificial MeatOthers

Get a Sample PDF Report:https://www.reporthive.com/request_sample/2165893

The key players mentioned above come mapped with their complete strategic profiling correspondingly as where the global scope is considered. Talking about the competitive landscape presented in this report, our research analysts have ensured studying all core capabilities of the industry players. Overall the study helps recognizing the profit-making opportunities and also assists in the design of future plans.

Stem Cell Artificial Meat Market Segments:The report has been segregated into several different segmentscomprising, product type, application, end users, regions, and many other applicable to the Stem Cell Artificial Meat market landscape. Each and every entries belonging to the segments are thoroughly discussed in a simplified structure for better understanding of the market from the readers perspective. Segmental analysis includes breaking down of the individual segments into Industry share, which also includes growth analysis depicted in terms of CAGR scrutinized in the report.

Regional Analysis:Besidessegmental breakdown, the report is highly structured into region wise study. The regional analysis comprehensively done by the researchershighlights key regions and their dominating countries accounting for substantial revenue share in the Stem Cell Artificial Meat market. The study helps understanding how the market will fare in the respective region, while also mentioning the emerging regions growing with a significant CAGR. The following are the regions covered in this report. North America: United States, Canada, and Mexico. South & Central America: Argentina, Chile, and Brazil. Middle East & Africa: Saudi Arabia, UAE, Turkey, Egypt and South Africa. Europe: UK, France, Italy, Germany, Spain, and Russia. Asia-Pacific: India, China, Japan, South Korea, Indonesia, Singapore, and Australia.

You may also request a customized PDF template through the link below:https://www.reporthive.com/request_customization/2165893

Report Customization:We are always open to report customization. If the downloaded template is not as per your need, please connect with our sales team to initiate the process of customization.Let us know if you have any special requirements focused on a specific segment or region.

Research Methodology:We incorporate both primary and secondary research methodologies to produce highly reliable data and growth assumptions for the future. Our data triangulation method includes analysis of several market scenarios and product mappings, which is then broken down into highly organized and statistical pre-sets.

About Us:Our research base consists of a wide spectrum of premium market research reports. Apart from comprehensive syndicated research reports, our in-house team of research analysts leverages excellent research capabilities to deliver highly customized tailor-made reports. The market entry strategies presented in our reports has helped organizations of all sizes to generate profits by making timely business decisions. The research information including market size, sales, revenue, and competitive analysis offered, is the product of our excellence in the market research domain.

Contact Us:

Report Hive Research

500, North Michigan Avenue,

Suite 6014,

Chicago, IL 60611,

United States

Website: https://www.reporthive.com

Email: [emailprotected]

Phone: +1 312-604-7084

See the original post:
Stem Cell Artificial Meat : Industry Analysis and Forecast 2020 2025 By Key Players-, Beyond Meat, Impossible Foods, Memphis Meats, Boca Foods -...

Astrocytes Show Protective Role in Early-stage ALS – Technology Networks

Motor neuron disease is a degenerative condition which destroys the nerve cells (motor neurons) in the brain and spinal cord, which control movement, speech, swallowing and breathing. The most common type of motor neuron disease is amyotrophic lateral sclerosis (ALS), which affects around 5,000 people in the UK at any one time.A new study found that in this disease, the motor neurons in the brain and spinal cord become sick and die when a protein, called TDP-43, misfolds and accumulates in the wrong place within the motor neurons. Conversely, when this happens in a type of cell that supports motor neurons, called astrocytes, these cells appear comparatively resistant and survive.

When these two types of cells are close together, the more-resistant astrocytes are able to protect motor neurons from the misfolded protein. This rescue-mechanism helps the motor neurons, which are needed to control muscles, live longer.

The role astrocytes have played in dealing with toxic forms of TDP-43 in motor neurons has not been previously well documented in motor neuron disease. Its exciting that weve now found that they may play an important protective role in the early-stages of this disease, explains Phillip Smethurst, lead author. This has huge therapeutic potential finding ways to harness the protective properties of astrocytes could pave the way to new treatments. This could prolong their rescue function or find a way to mimic their behavior in motor neurons so that they can protect themselves from the toxic protein.

This research also established a new model for studying motor neuron disease. This new method more closely resembles the disease in patients as it uses healthy human stem cells, derived from skin cells, and spinal cord tissue samples donated by patients with motor neuron disease, collected post-mortem.

It is thanks to the selfless donations from people with motor neuron disease, that we were able to study the interplay between motor neurons and astrocytes in conditions that closely resemble what happens in humans. These human cell models are a powerful tool for further studies of motor neuron disease and in the hunt for effective therapies. explains Katie Sidle, co-senior author.

For the first time, we have been able to create a model of sporadic motor neuron disease by essentially transferring the toxic TDP-43 protein from post-mortem tissue into healthy human stem cell-derived motor neurons and astrocytes in order to understand how each cell type responds to this insult, both in isolation and when mixed together. The insights made in this work are testament to the power of creative collaboration and interdisciplinarity. It is through many years working together as a group of clinicians, pathologists, stem cell biologists, protein biochemists and other experts, and with a joint aim of increasing knowledge about motor neuron disease (to ultimately help find a cure), that these results have been possible, says Rickie Patani, co-senior author.ReferenceSmethurst et al. (2020) Distinct responses of neurons and astrocytes to TDP-43 proteinopathy in amyotrophic lateral sclerosis. Brain. DOI: https://doi.org/10.1093/brain/awz419

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

See more here:
Astrocytes Show Protective Role in Early-stage ALS - Technology Networks

Mammals Can Delay The Development of Their Embryos, According to Recent Research – Dual Dove

Recent research sheds light on something quite peculiar, exploring a reproductive mystery that is present in more than 130 species of mammals. A team of researchers conducted by Abdiasis Hussein, an associate director of UW Medicines Institute for Stem Cell, also a UW professor of biochemistry, realized the intriguing findings on mammals.

The results not only bring more details for the understanding of postponed embryo implantation. It also indicates how some quickly splitting cells, such as those present in tumors, turn to be inactive.

To find out what leads to a biochemical hold-and-release on embryonic production, the team provoked diapause in a female mouse by decreasing the estrogen rates. Then, they realized a comparison of the diapause embryos to pre-implantation and post-implantation ones. They also provoked diapause in mouse embryonic stem cells by weakening the cells, and analyze those to actively developing mouse embryonic stem cells.

Researchers had also performed comprehensive investigations of how metabolic and signaling pathways manage both the inactive and active phases of mouse embryos and mouse embryonic stem cells in lab vessels.

Metabolism involves the life-supporting chemical actions cells take out to turn substances into energy, develop materials, and discharge waste. By examining those reactions final actions, dubbed metabolites, the researchers could start to realize the full picture of that occurs to cause diapause and how cells are delivered from its grips.

Bears, seals, weasel-like animals, or armadillos, experience seasonal diapause, as a regular part of their reproductive periods. Many classes of bears, for example, breed in the early stages of spring and sometimes even in early summer. The female then uncontrollable hunts for food, and only when it reaches sufficient weight and body fat, one or more of her embryos implant a few months later after she moves to her cave. Any baby bears would be born in late winter.

Ethelene is the main editor on DualDove, she likes to write on the latest science news.

Read the rest here:
Mammals Can Delay The Development of Their Embryos, According to Recent Research - Dual Dove

Banff resident leaves $600,000 legacy to fight blindness – The Crag and Canyon

Doreen Powles legacy will impact people around the world as research discoveries transform lives by leading to treatments that restore sight. Thank you, Doreen, for your generosity, said Doug Earle, President and CEO, Fighting Blindness Canada.

Fighting Blindness Canada said they are grateful for the legacy gift of $600,000 by Banff resident, the late Doreen Marjorie Powles to fight blindness.

The announcement was made in Banff at the annual meeting of the Canadian Retina Society where Canadas retina specialists have gathered to share the latest in research and new treatments.

Fighting Blindness Canada is honoured to announce that Dr. Elizabeth M Simpson at the University of British Columbia is the recipient of the Doreen Powles Award to End Blindness for her project entitled Using gene therapy to Treat Congenital Blindness.

Doreen Powles spent her life in Banff where she lived with a blinding eye disease called congenital blindness. Her blindness was present at birth with reduced ability to detect light and colour, severe nearsightedness and involuntary movements of the eye.

Robert Smyth, executor of Doreen Powles estate said, Doreen was an only child. She left her entire estate to finance eye research, providing scholarships for aspiring researchers and helping people living with blindness. She would be excited by Fighting Blindness Canadas ground-breaking research to restore sight.

G.P. Powles, her father, was a partner in Hornibrook and Powles Insurance in Banff and a Rotarian.

Mr. Powles searched the world at great expense to find a cure for his daughters blindness without success.

Doreen Marjorie Powles graduated in 1952 from the University of British Columbia with a Bachelor of Arts.

Fighting Blindness Canada (FBC) is Canadas leading private funder of vision research. Over our 45-year history, we have invested over $40 million to support vision research and education across Canada with over 200 research grants that have led to over 600 new discoveries in areas such as stem cell research, neuroprotective therapies, technological developments, pharmaceuticals, and gene therapies.

View post:
Banff resident leaves $600,000 legacy to fight blindness - The Crag and Canyon